On June 9, RemeGen rose 5.68% in regular trading, trading at 72.35 HKD/share, with trading volume of HKD 236 million. The rally was driven by the announcement that its core product Telitacicept received marketing approval for two new indications.

According to the company disclosure, injectable Telitacicept was approved for the treatment of Sjogren's syndrome, while Telitacicept injection for IgA nephropathy received conditional approval via priority review. Telitacicept is the world's first BLyS/APRIL dual-target innovative biologic, simultaneously inhibiting BLyS and APRIL binding to B-cell surface receptors to block abnormal B-cell differentiation and maturation. The Sjogren's syndrome Phase III trial represents the first dual-target biologic globally to achieve strongly positive results in this indication, while IgA nephropathy Phase III data has been published in The New England Journal of Medicine, underscoring its clinical significance.

Within the Biotechnology sector, performance was mixed. Among peers, AKESO down 0.05%, INNOVENT BIO up 0.96%, BEIGENE down 1.04%, SKB BIO up 4.14%, 3SBIO up 4.01%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)